Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on the Development of Gene Therapy for Bladder Cancer
Shots:
- Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive- non-muscle invasive bladder cancer
- Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M and will get MAA for the therapy if approved by the US FDA.
- Nadofaragene firadenovec is an adenovirally mediated interferon alfa-2b gene therapy being developed in P-III study as a treatment for patients with high-grade- BCG unresponsive- NMIBC and has received FDA’s PR & BT designation. The US FDA has accepted BLA filing for Nadofaragene firadenovec
Click here to read full press release/ article | Ref: Blackstone | Image: VC Circle
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
